Drug search by name

Mekinist and Cardiomyopathy

Result of checking the interaction of drug Mekinist and disease Cardiomyopathy for safety when used together.

Check result:

Mekinist <> Cardiomyopathy

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Cardiomyopathy, including cardiac failure may occur with the use of trametinib. It is recommended that all patients undergo a cardiovascular evaluation including echocardiogram at baseline to document normal left ventricular ejection fraction (LVEF) and repeat echocardiograms at Week 4, Week 12, and every 12 weeks thereafter as clinically appropriate. Withhold trametinib for up to 4 weeks if absolute LVEF value decreases by 10% from pretreatment values and is less than the lower limit of normal (LLN). Permanently discontinue trametinib for symptomatic cardiomyopathy or persistent, asymptomatic LV dysfunction of >20% from baseline that is below LLN and that does not resolve within 4 weeks.

Mekinist

Generic Name: trametinib

Brand Name: Mekinist

Synonyms: n.a.

What is Mekinist?